April 1, 2011 –Results from the RADAR Phase 2b clinical trial will be announced at the i2 Summit during the American College of Cardiology (ACC) 2011 Annual Scientific Session and Expo. The trial examined the Reg1 anticoagulation system, from Regado Biosciences.
Data will be presented by Thomas J. Povsic, M.D., Ph.D., assistant professor of medicine at Duke University.
Reg1 comprises a two-component system: a highly selective Factor IXa inhibiting aptamer, pegnivacogin, and its complementary specific active control agent, anivamersen. Anivamersen can be used to selectively reverse (completely or partially) the anticoagulant effect of pegnivacogin in real time.
For more information: www.regadobio.com